LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2)
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
LUNAR-2 is a pivotal, randomized, open-label study that aims to evaluate the effectiveness and safety of Tumor Treating Fields (TTFields) concomitantly administered with pembrolizumab and platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer (NSCLC).
The primary objectives of the study are to assess overall survival (OS) and progression-free survival (PFS) in subjects treated with TTFields, pembrolizumab, and platinum-based chemotherapy compared to those treated with pembrolizumab and platinum-based chemotherapy alone. PFS will be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
The secondary endpoints of this study will evaluate PFS and OS, stratified by the specific histological subtype of NSCLC and PD-L1 Tumor Proportion Score (TPS).
The population will consist of subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and will be stratified as follow:
- Histology - Squamous vs. non-squamous
- PD-L1 expression level - TPS <1% vs. 1% ≤TPS <50% vs. TPS ≥50%
- Prior treatment with immunotherapy - yes vs. no
The study will be conducted globally at approximately 130 participating sites. The study device, NovoTTF-200T, is a portable, battery-operated system that delivers TTFields at a frequency of 150kHz. It utilizes insulated transducer arrays to deliver electric forces intended to disrupt cancer cell division.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Innsbruck, Austria, 6020
- Active, not recruiting
- Universitaetsklinik fuer Innere Medizin V Innsbruck
-
Salzburg, Austria, 5020
- Active, not recruiting
- University Hospital Salzburg
-
Vienna, Austria, 1210
- Active, not recruiting
- Karl Landsteiner Institut fur Lungenforschung und pneumologische Onkologie c/o Klinik Floridsdorf
-
-
-
-
-
Brussels, Belgium, 1200
- Active, not recruiting
- Cliniques universitaires Saint-Luc
-
Ghent, Belgium, 9000
- Active, not recruiting
- AZ Maria Middelares - Campus Maria Middelares
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Recruiting
- Cross Cancer Institute/University of Alberta
-
Contact:
- Haidar El Darsa
- Phone Number: (780) 432-8340
- Email: Haidar.ElDarsa@CancerCareAlberta.ca
-
Principal Investigator:
- Haidar El Darsa
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Recruiting
- The Ottawa Hospital Cancer Centre General Campus
-
Principal Investigator:
- Garth Nicholas
-
Contact:
- Garth Nicholas
- Phone Number: 70175 613-737-7700
- Email: gnicholas@toh.ca
-
Toronto, Ontario, Canada, M4N 3M5
- Recruiting
- Sunnybrook Health Sciences Center
-
Contact:
- Vaishali Krishnanandan
- Phone Number: 67955 416-480-5000
- Email: vaishali.krishnanandan@sunnybrook.ca
-
Principal Investigator:
- Susanna Cheng
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 4M1
- Recruiting
- CHUM
-
Principal Investigator:
- David Roberge
-
Contact:
- Mom Phat
- Phone Number: 514-890-8254
- Email: mom.phat.chum@ssss.gouv.qc.ca
-
-
-
-
-
Olomouc, Czechia, 779 00
- Terminated
- Fakultni nemocnice Olomouc FNOL
-
Ostrava, Czechia, 70300
- Active, not recruiting
- Nemocnice Agel Ostrava-Vitkovice / Agel Ostrava-Vitkovice Hospital
-
Prague, Czechia, 12808
- Active, not recruiting
- General University Hospital in Prague
-
-
-
-
-
Créteil, France, 94010
- Recruiting
- Centre Hospitalier Intercommunal de Creteil
-
Contact:
- Christos Chouaid
- Phone Number: +33 1 57 02 20 70
- Email: christos.chouaid@chicreteil.fr
-
Limoges, France, 87000
- Terminated
- CHU Limoges
-
Marseille, France, 13003
- Terminated
- Hopital Europeen
-
Nantes, France, 44277
- Recruiting
- Hopital Prive du Confluent
-
Principal Investigator:
- Cyriac Blonz
-
Contact:
- Cyriac Blonz
- Phone Number: +33 2 28 27 20 88
- Email: BLONZ.CYRIAC@groupeconfluent.fr
-
Paris, France, 75005
- Recruiting
- Institut Curie
-
Contact:
- Nicolas Girard
- Phone Number: 33144324677
- Email: nicolas.girard2@curie.fr
-
Pessac, France, 33604
- Recruiting
- CHU de Bordeaux
-
Contact:
- Claire Bardel
- Phone Number: +33 5 57 65 63 38
- Email: claire.bardel@chu-bordeaux.fr
-
Pierre-Bénite, France, 69495
- Terminated
- Centre Hospitalier Lyon Sud
-
Strasbourg, France, 67091
- Recruiting
- Nouvel Hopital Civil (NHC)
-
Contact:
- Celine Mascaux
- Phone Number: 33-3-69 55 06 44
- Email: celine.mascaux@chru-strasbourg.fr
-
-
-
-
-
Berlin, Germany, 13125
- Active, not recruiting
- Evangelische Lungenklinik Berlin
-
Giessen, Germany, 35392
- Recruiting
- University Hospital Giessen, ZIM IV
-
Contact:
- Anika Holzapfel
- Phone Number: +49 641 985 59263
- Email: Anika.Holzapfel@uniklinikum-giessen.de
-
Halle, Germany, 06120
- Recruiting
- Krankenhaus Martha-Maria Halle-Dolau
-
Principal Investigator:
- Wolfgang Schuette
-
Contact:
- Franziska Gebauer
- Phone Number: +49 345 559 1434
- Email: franziska.gebauer@martha-maria.de
-
Heidelberg, Germany, 69126
- Active, not recruiting
- Thoraxklinik Heidelberg
-
Löwenstein, Germany, 74245
- Terminated
- Klinik Loewenstein gGmbH
-
Oldenburg, Germany, 26121
- Terminated
- Pius-Hospital Oldenburg
-
-
-
-
-
Farkasgyepű, Hungary, 8582
- Active, not recruiting
- Farkasgyepui Tudogyogyintezet
-
Kecskemét, Hungary, 6000
- Active, not recruiting
- Bacs-Kiskun Varmegyei Oktatokorhaz
-
Szekszárd, Hungary, 7100
- Recruiting
- Tolna Varmegyei Balassa Janos Korhaz
-
Contact:
- Yousuf Al-Farhat
- Phone Number: +36 30 644 1744
- Email: yalfarhat@gmail.com
-
-
-
-
-
Afula, Israel, 1834111
- Active, not recruiting
- Emek Medical Center
-
Haifa, Israel, 34561
- Active, not recruiting
- Bnai zion MC
-
-
-
-
-
Alessandria, Italy, 15121
- Terminated
- A.O. SS. Antonio e Biagio e Cesare Arrigo di Alessandria
-
Bergamo, Italy, 24125
- Active, not recruiting
- Humanitas Gavazzeni
-
Ferrara, Italy, 44124
- Active, not recruiting
- Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna
-
Meldola, Italy, 47014
- Recruiting
- IRCCS - Istituto Romagnolo per lo Studio Dei Tumori, Dino Amadori
-
Contact:
- Angelo Delmonte
- Phone Number: +39 0543 739100
- Email: angelo.delmonte@irst.emr.it
-
Pesaro, Italy, 61122
- Active, not recruiting
- Azienda Sanitaria Territoriale Pesaro Urbino
-
Roma, Italy, 00128
- Terminated
- Universita Campus Bio-Medico di Roma (UCBM) - Policlinico Universitario
-
Rome, Italy, 00186
- Terminated
- Ospedale Isola Tiberina Gemelli
-
Siena, Italy, 53100
- Terminated
- Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte
-
-
-
-
Osaka
-
Osaka, Osaka, Japan, 541-8567
- Recruiting
- Osaka International Cancer Institute
-
Contact:
- Kei Kunimasa
- Phone Number: 06-6945-1181
- Email: kei.kunimasa@oici.jp
-
Principal Investigator:
- Kei Kunimasa
-
Sakai, Osaka, Japan, 590-0197
- Recruiting
- Kindai University Hospital
-
Principal Investigator:
- Hidetoshi Hayashi
-
Contact:
- Hidetoshi Hayashi
- Phone Number: 81-72-288-7222
- Email: hidet31@med.kindai.ac.jp
-
-
Saitama
-
Hidaka, Saitama, Japan, 350-1298
- Recruiting
- Saitama Medical University International Medical Center
-
Contact:
- Saitama Medical University International Medical Center
- Phone Number: 042-984-4183
- Email: chikenme@saitama-med.ac.jp
-
-
Tokyo
-
Bunkyo, Tokyo, Japan, 113-8431
- Recruiting
- Juntendo University
-
Principal Investigator:
- Takehito Shukuya
-
Contact:
- Takehito Shukuya
- Phone Number: 81-3-3814-5672
- Email: tshukuya@juntendo.ac.jp
-
Chuo-ku, Tokyo, Japan, 104-0045
- Recruiting
- National Cancer Center Hospital
-
Principal Investigator:
- Hidehito Horinouchi
-
Contact:
- Hidehito Horinouchi
- Phone Number: 81-3542-2511
- Email: hhorinou@ncc.go.jp
-
-
-
-
-
Arnhem, Netherlands, 6815AD
- Terminated
- Rijnstate Ziekenhuis
-
Friesland, Netherlands, 8934 AD
- Terminated
- Medisch Centrum Leeuwarden (MCL) - Oncologisch Centrum Leeuwarden (OCL)
-
Harderwijk, Netherlands, 3844 DG
- Active, not recruiting
- St. Jansdal ziekenhuis
-
Utrecht, Netherlands, 3543 AZ
- Terminated
- St Antonius Ziekenhuis
-
-
-
-
-
Poznan, Poland, 60-693
- Terminated
- Uniwersytecki Szpital Kliniczny
-
-
-
-
-
Singapore, Singapore, 168583
- Active, not recruiting
- NCCS Singapore
-
Singapore, Singapore, 329563
- Terminated
- Curie Oncology
-
Singapore, Singapore, 574623
- Active, not recruiting
- Icon Cancer Centre Singapore (Singapore Oncology Consultants)
-
-
-
-
-
Barcelona, Spain, 8916
- Recruiting
- Institut Catala d'Oncologia
-
Contact:
- Enric Carcereny Costa
- Phone Number: +34 677 254 583
- Email: ecarcereny@iconcologia.net
-
Lleida, Spain, 25198
- Active, not recruiting
- Hospital Universitario Arnau de Vilanova
-
Madrid, Spain, 28027
- Active, not recruiting
- Clinica Universidad de Navarra (Madrid)
-
Madrid, Spain, 28034
- Terminated
- Hospital Ruber Internacional
-
Málaga, Spain, 29010
- Recruiting
- Hospital Regional Universitario de Malaga
-
Contact:
- Airam Padilla Alvarez
- Phone Number: +34 951 308 130
- Email: airampadillaalvarez@gmail.com
-
Pamplona, Spain, 31008
- Recruiting
- Clinica Universidad de Navarra
-
Contact:
- Miguel Fernandez de Sanmamed Gutierrez
- Phone Number: +34 948255400
- Email: msanmamed@unav.es
-
-
Alicante
-
Elche, Alicante, Spain, 3293
- Terminated
- Hospital Universitario del Vinalopo
-
-
Andalusia
-
Seville, Andalusia, Spain, 41013
- Active, not recruiting
- Hospital Universitario Virgen del Rocio
-
-
Catalonia
-
Barcelona, Catalonia, Spain, 8017
- Recruiting
- Clinica Mi Tres Torres Barcelona - Giromed Institute
-
Contact:
- Carlos Cabrera Galvez
- Phone Number: +34 932 287 445
- Email: ccabrera@uomi.es
-
-
Madrid
-
Torrejón de Ardoz, Madrid, Spain, 28850
- Recruiting
- Hospital Universitario de Torrejon
-
Contact:
- Luis Cabezon Gutierrez
- Phone Number: +34 916262626
- Email: lcabezon@torrejonsalud.com
-
-
-
-
-
Baden, Switzerland, 5404
- Terminated
- Cantonal Hospital Baden
-
Fribourg, Switzerland, 1752
- Active, not recruiting
- HFR Freiburg-Kantonsspital
-
-
-
-
Greater London
-
London, Greater London, United Kingdom
- Recruiting
- Charing Cross Hospital
-
Contact:
- Denebeth Calla
- Phone Number: 020-331-10291
- Email: Denebeth.calla@nhs.net
-
Principal Investigator:
- Waleed Mohammed
-
-
Leicestershire
-
Leicester, Leicestershire, United Kingdom, LE1 5WW
- Recruiting
- University Hospitals of Leicester NHS Trust
-
Contact:
- Clare Belcher
- Phone Number: 01162586935
- Email: clare.belcher2@nhs.net
-
Principal Investigator:
- Sean Dulloo
-
-
London
-
London, London, United Kingdom, SW3 6JJ
- Recruiting
- The Royal Marsden NHS Foundation Trust
-
Contact:
- Michael Davidson
- Phone Number: +44 20 7352 8171
- Email: lung.trials@rmh.nhs.uk
-
-
Merseyside
-
Liverpool, Merseyside, United Kingdom, L7 8YA
- Recruiting
- Clatterbridge Cancer Centre - Liverpool
-
Principal Investigator:
- Carles Escriu
-
Contact:
- William McCaig
- Phone Number: 07795 129946
- Email: william.mccaig1@nhs.net
-
-
Sutton
-
Sutton, Sutton, United Kingdom, SM2 5PT
- Recruiting
- The Royal Marsden NHS Foundation Trust - Sutton
-
Contact:
- Michael Davidson
- Phone Number: +44 20 7352 8171
- Email: lung.trials@rmh.nhs.uk
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Terminated
- Central Alabama Research
-
-
Arizona
-
Goodyear, Arizona, United States, 85338
- Active, not recruiting
- Western Regional Medical Center, LLC
-
-
California
-
Fullerton, California, United States, 92835
- Recruiting
- St. Jude Herritage Medical Group
-
Contact:
- Larissa Ulloa
- Phone Number: 800-627-8106
- Email: larissa.lacson@providence.org
-
Newport Beach, California, United States, 92663
- Recruiting
- Hoag Family Cancer Institute - Hoag Memorial Hospital
-
Contact:
- Patrice Jones
- Phone Number: 949-764-5501
- Email: Patrice.Jones@hoag.org
-
Sacramento, California, United States, 95816
- Active, not recruiting
- Sutter Institute for Medical Research
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Recruiting
- Baptist MD Anderson Cancer Center, Baptist Health
-
Contact:
- Vanessa Tolsa
- Phone Number: 305-915-6496
- Email: vanessa.tolsa@bmcjax.com
-
Principal Investigator:
- John Vu
-
Ocala, Florida, United States, 34474
- Terminated
- Florida Cancer Affiliates - Ocala Oncology
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Maya Douglas
- Phone Number: 813-745-0969
- Email: maya.douglas@moffitt.org
-
-
Illinois
-
Barrington, Illinois, United States, 60010
- Active, not recruiting
- Northwest Oncology & Hematology
-
Elmhurst, Illinois, United States, 60126
- Active, not recruiting
- Elmhurst Hospital Nancy Knowles Cancer Center
-
Naperville, Illinois, United States, 60540-6766
- Terminated
- Edward Cancer Center
-
Zion, Illinois, United States, 60099
- Recruiting
- Cancer Treatment Centers of America (CTCA)
-
Contact:
- Sylvia Schneiderman
- Phone Number: 1-847-746-6983
- Email: sylvia.schneiderman@coh.org
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46845
- Recruiting
- Parkview Packnett Family Cancer Institute
-
Principal Investigator:
- Brian Chang
-
Contact:
- Brian Chang, Dr.
- Phone Number: 1-833-724-8326
- Email: brian2.chang@parkview.com
-
Indianapolis, Indiana, United States, 46237
- Terminated
- Franciscan Health Indianapolis
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- Active, not recruiting
- University of Kansas Cancer Center
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
- Terminated
- Luminis Health Radiation Oncology - Anne Arundel Health System
-
-
Missouri
-
Kansas City, Missouri, United States, 64154
- Active, not recruiting
- University of Kansas Cancer Center - North
-
Lee's Summit, Missouri, United States, 64064
- Active, not recruiting
- University of Kansas Cancer Center - Lee's Summit
-
Overland, Missouri, United States, 66210
- Active, not recruiting
- University of Kansas Cancer Center - Overland Park
-
-
New York
-
New Hyde Park, New York, United States, 11042
- Terminated
- New York Cancer & Blood Specialists (NYCBS)
-
New York, New York, United States, 10028
- Terminated
- New York Cancer & Blood Specialists (NYCBS)
-
Rochester, New York, United States, 14642
- Terminated
- University of Rochester Medical Center
-
Shirley, New York, United States, 11967
- Terminated
- New York Cancer & Blood Specialists (NYCBS)
-
The Bronx, New York, United States, 10469
- Terminated
- New York Cancer & Blood Specialists (NYCBS)
-
-
North Carolina
-
Cary, North Carolina, United States, 27518
- Recruiting
- WakeMed Health & Hospitals
-
Contact:
- Taylor Childress
- Phone Number: 14842 919-350-1700
- Email: tchildress@wakemed.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Abramson Cancer Center
-
Contact:
- Ryan Roddy
- Phone Number: 267-408-3199
- Email: ryan.roddy@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, United States, 15212
- Recruiting
- AHN Cancer Center
-
Contact:
- Ariel Lopez-Chavez
- Phone Number: 412-518-5025
- Email: clinicaltrials@ahn.org
-
-
Texas
-
Dallas, Texas, United States, 75235
- Recruiting
- UT Southwestern Medical Center
-
Contact:
- Ebele Mbanugo
- Phone Number: 214-645-0326
- Email: ebele.mbanugo@utsouthwestern.edu
-
Dallas, Texas, United States, 75235
- Recruiting
- Old Parkland Hospital Hematology Oncology Clinic
-
Contact:
- Ebele Mbanugo
- Phone Number: 214-645-0326
- Email: ebele.mbanugo@utsouthwestern.edu
-
Edinburg, Texas, United States, 78539
- Recruiting
- DHR Health Oncology Institute
-
Contact:
- Edgar Lopez
- Phone Number: 956-362-2394
- Email: ed.lopez@dhr-rgv.com
-
Houston, Texas, United States, 77030
- Recruiting
- Houston Methodist Cancer Center
-
Principal Investigator:
- Jun Zhang
-
Contact:
- Nicole Barrios
- Phone Number: 713-441-5607
- Email: nkbarrios@houstonmethodist.org
-
Richardson, Texas, United States, 75082
- Recruiting
- Methodist Richardson Cancer Center
-
Contact:
- Crystee Cooper
- Phone Number: 214-947-1280
- Email: ClinicalResearch@mhd.com
-
San Antonio, Texas, United States, 78229
- Terminated
- Jason Bates at University of Texas Health Science Center
-
-
Washington
-
Auburn, Washington, United States, 98001
- Terminated
- MultiCare Regional Cancer Center
-
Gig Harbor, Washington, United States, 98335
- Terminated
- MultiCare Regional Cancer Center
-
Puyallup, Washington, United States, 98372
- Terminated
- MultiCare Regional Cancer Center
-
Spokane, Washington, United States, 99218
- Terminated
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Tacoma, Washington, United States, 98405
- Terminated
- MultiCare Institute for Research & Innovation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
-
≥22 years of age in the USA
≥18 years of age outside of the USA.
-
Histologically or cytologically diagnosis of stage 4 (according to Version 8 of the American Joint Committee on Cancer [AJCC] criteria) non-squamous or squamous NSCLC.
-
Evaluable (measurable or non-measurable) disease in the thorax per RECIST v1.1.
-
Have not received prior systemic treatment for their metastatic NSCLC. Subjects who received adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease are eligible if the therapy was completed at least 12 months prior to the development of metastatic disease.
-
ECOG Performance Status (PS) of 0-1.
-
Adequate hematologic and end-organ function
o For subjects not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN (unless participant is receiving anticoagulant therapy as long as INR or aPTT is within therapeutic range of intended use of anticoagulants).
-
A female participant is eligible to participate if she is not pregnant, not breastfeeding
-
If male subject with a female partner(s) of child-bearing potential, must agree to use an effective contraception
-
All subjects must sign written informed consent.
Exclusion Criteria:
All individuals meeting any of the following exclusion criteria will be excluded from study participation:
-
Mixed small cell and NSCLC histology.
-
EGFR sensitizing mutation and/or ALK translocation, and/or ROS1 and/or RET targetable gene rearrangement, and/or METex14 skipping mutation, and/or NTRK1/2 gene fusion and/or BRAF V600 mutations directed therapy is indicated or planned for other targeted therapy, where such testing and therapy is locally approved and available.
-
Has received systemic therapy for metastatic disease.
-
Had major surgery <3 weeks prior to randomization
-
Received radiation therapy to the lung that is > 30 Gy within 6 months of randomization.
-
Has received prior radiotherapy within 2 weeks of randomization. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
-
Is expected to require any other form of antineoplastic therapy while on study.
-
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Note: Subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
-
Has symptomatic Central Nervous System (CNS) metastases and/or carcinomatous meningitis. Subjects with asymptomatic CNS metastases or with previously treated brain metastases may participate provided they were treated before randomization (if applicable) and are neurologically stable and without requirement of steroid treatment for at least 7 days prior to randomization.
-
Has active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
-
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior randomization. Subjects with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study.
-
Had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors or mechanisms in the 12 months prior to randomization.
-
Participation in another clinical study with an investigational agent or device during the 4 weeks prior to randomization.
-
Concurrent treatment with other experimental treatments for NSCLC while in the study.
-
Has a known sensitivity to any component of the planned systemic therapies (pembrolizumab, cisplatin/carboplatin, pemetrexed/paclitaxel/nab-paclitaxel) .
-
Pregnant or breastfeeding
-
Admitted to an institution by administrative or court order.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1: NovoTTF-200T, Pembrolizumab, and Platinum-based Chemotherapy
Subjects in this arm receive three treatments - TTFields using the NovoTTF-200T device, pembrolizumab, and platinum-based chemotherapy. |
The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death. Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells. Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer |
|
Active Comparator: Arm 2: Pembrolizumab and Platinum-based Chemotherapy
Subjects in this arm receive two treatments - pembrolizumab and platinum-based chemotherapy. |
Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells. Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival (OS)
Time Frame: up to 6 years
|
To compare OS in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy compared to OS of those treated with pembrolizumab and platinum-based chemotherapy alone (superiority analysis). |
up to 6 years
|
|
Progression Free Survival (PFS)
Time Frame: up to 6 years
|
To compare PFS per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy compared to PFS of those treated with pembrolizumab and platinum-based chemotherapy alone (superiority analysis) |
up to 6 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression Free Survival (PFS)
Time Frame: up to 6 years
|
Progression Free Survival (PFS) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to histology. |
up to 6 years
|
|
Overall Survival (OS)
Time Frame: up to 6 years
|
Overall Survival (OS) in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to histology. |
up to 6 years
|
|
Progression Free Survival (PFS)
Time Frame: up to 6 years
|
PFS per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to PD-L1 Tumor Proportion Score (TPS). |
up to 6 years
|
|
Overall Survival (OS)
Time Frame: up to 6 years
|
OS in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone according to PD-L1 TPS. |
up to 6 years
|
|
Progression Free Survival (PFS)
Time Frame: up to 6 years
|
PFS per RECIST v1.1 as assessed by BICR at 6 (PFS6), 12 (PFS12), 24 (PFS24), and 36 (PFS36) months in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
1, 2, and 3-year Survival Rate
Time Frame: up to 6 years
|
1-, 2- and 3-year survival rate in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Objective Response Rate (ORR)
Time Frame: up to 6 years
|
Objective Response Rate (ORR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Duration of Response (DoR)
Time Frame: up to 6 years
|
Duration of Response (DoR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Disease Control Rate (DCR)
Time Frame: up to 6 years
|
Disease Control Rate (DCR) per RECIST v1.1 as assessed by BICR, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Progression Free Survival (PFS)
Time Frame: up to 6 years
|
PFS per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Objective Response Rate (ORR)
Time Frame: up to 6 years
|
ORR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Duration of Response (DoR)
Time Frame: up to 6 years
|
DoR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Disease Control Rate (DCR)
Time Frame: up to 6 years
|
DCR per RECIST v1.1 as assessed by the investigator, in subjects treated with TTFields concomitant with pembrolizumab and platinum-based chemotherapy and of those treated with pembrolizumab and platinum-based chemotherapy alone. |
up to 6 years
|
|
Adverse Events
Time Frame: up to 6 years
|
Toxicity profile of TTFields concomitant with pembrolizumab and platinum-based chemotherapy. The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments. |
up to 6 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplastic Processes
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Pathological Conditions, Signs and Symptoms
- Neoplasm Metastasis
- Carcinoma, Non-Small-Cell Lung
- Inorganic Chemicals
- Platinum Compounds
- pembrolizumab
Other Study ID Numbers
Other Study ID Numbers
- EF-44
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.